Reveal Pharma

Gadolinium-free MRI contrast agents for all patients
Precision imaging to deepen insight
Invented @MGHMartinos science: see pin
#ContrastMatters #ImageWisely

[Reveal Pharma @revealpharma]

https://t.co/tLT8HCSrmW

[Reveal Pharma @revealpharma]

Delighted to announce: the first subjects have been dosed in a Phase 1 clinical study of RVP-001, the first gadolinium-free general purpose MRI contrast agent to enter clinical trials.

Grateful thanks for @theNCI support

https://t.co/F41slYNdPi

#ContrastMatters #ImageWisely

[Reveal Pharma @revealpharma]

The Phase 2 clinical study of the gadolinium-free MRI contrast agent, RVP-001, is recruiting!

This clinical imaging study is in patients with gadolinium-enhancing central nervous system (CNS) lesions. Sites include Harvard (MGH+BWH), Duke, and Yale.

https://t.co/f28DH3PhSP

[Reveal Pharma @revealpharma]

@theNCI Read more about the Phase 1 study of RVP-001 here:
https://t.co/2PRJQaWuXR

[Reveal Pharma @revealpharma]

Delighted to announce: the first subjects have been dosed in a Phase 1 clinical study of RVP-001, the first gadolinium-free general purpose MRI contrast agent to enter clinical trials.

Grateful thanks for @theNCI support

https://t.co/F41slYNdPi

#ContrastMatters #ImageWisely

[Reveal Pharma @revealpharma]

Reveal is excited to be presenting at #BIO2024!

Don't miss Dr Srini Mukundan's presentation: Monday, June 3rd, 4:15 pm Presentation Room 1
+ clinical studies of gadolinium-free MRI contrast agent RVP-001
+ Fibrogenesis imaging agent

Thanks to @NIH @nihseed @theNCI support!

[This account is no longer active @nihseed]

More than 30 NIH-funded companies will pitch compelling biotech solutions at #BIO2024. Attending? Visit Booth 825 to connect with NIH companies and team members. See you there! 👀 @IAmBioTech #NIHSEED

[Helen Kim, MD @whatherad]

I believe this is the first time @PedRadJournal is addressing climate change in our field of pediatric radiology. Grateful for this collaboration to raise awareness of climate change in pediatric radiology. https://t.co/s4pq4N4IHf

[Reveal Pharma @revealpharma]

Thank you @nihseed @NCIsbir @NHLBI_SBIR @NIDDKgov for all the support and the opportunity to highlight Reveal's transformative impact for patients and the planet.

We had a good time at #BIO2023: 2 presentations, 4 days, so many meetings ... many great things to come!

[Reveal Pharma @revealpharma]

@adamhayden This is awesome!!! 💗

[Reveal Pharma @revealpharma]

@angryhacademic @amymitchellart My empathy. The experience of atypical or delayed reactions - and the difficulty of recognizing and accurately tracking down a causative connection - is a common thread & major challenge when studying reactions to gadolinium-based contrast agents.

[Reveal Pharma @revealpharma]

@angryhacademic @amymitchellart Well, we are [a small company with limited resources] trying to engage...

Given the low reported acute reactions to gadolinium-based contrast it does seem that the MCAS reaction to GBCAs is rare and/or under-recognized or under-reported.

[Reveal Pharma @revealpharma]

@angryhacademic @amymitchellart This rarity and unpredictability makes designing prospective studies exceptionally difficult.

[Reveal Pharma @revealpharma]

@angryhacademic @amymitchellart e.g. we know that gadolinium triggers nephrogenic systemic fibrosis (NSF) in some people with kidney disease.
But we can't predict which of those people will get NSF, and NSF can occur from days to years after exposure to gadolinium.

[Reveal Pharma @revealpharma]

@angryhacademic @amymitchellart I responded to the question "Are there any alternative contrast media for MRIs other than gadolinium?"

Our agent is the first general purpose alternative to gadolinium.

It is unclear (perhaps you can help me understand) whether the MCAS reaction is gadolinium-specific?

[Reveal Pharma @revealpharma]

@angryhacademic @amymitchellart Indeed: staged clinical studies are designed with the intent of testing safety in less vulnerable populations ahead of more vulnerable populations. It may not be practically possible to formally study a specific small population or rare condition.

[Reveal Pharma @revealpharma]

@angryhacademic @amymitchellart Early studies for most drugs avoid patients with a history of anaphylaxis - it is usually wise to assess safety and build experience in the general population first.

[Reveal Pharma @revealpharma]

@amymitchellart @angryhacademic There are no FDA-approved general purpose gadolinium-free MRI contrast agents.

We are developing a manganese based general purpose MRI agent, RVP-001, which is in clinical studies.

[Reveal Pharma @revealpharma]

@drakchaurasia General purpose gadolinium-free MRI contrast agents are not available yet, but in clinical studies.

https://t.co/V2VxcwPrWl

[Reveal Pharma @revealpharma]

Delighted to announce: the first subjects have been dosed in a Phase 1 clinical study of RVP-001, the first gadolinium-free general purpose MRI contrast agent to enter clinical trials.

Grateful thanks for @theNCI support

https://t.co/F41slYNdPi

#ContrastMatters #ImageWisely

[Mukesh Harisinghani @mharisinghani]

Complex trans sphincteric fistula; Looks like an abscess on T2 but is, in fact, enhancing inflammatory tissue on post-gadolinium T1 images; hence essential to have post-contrast images.

[Reveal Pharma @revealpharma]

... and the clinical study we performed last spring.

https://t.co/V2VxcwPrWl

[Reveal Pharma @revealpharma]

Delighted to announce: the first subjects have been dosed in a Phase 1 clinical study of RVP-001, the first gadolinium-free general purpose MRI contrast agent to enter clinical trials.

Grateful thanks for @theNCI support

https://t.co/F41slYNdPi

#ContrastMatters #ImageWisely

[Reveal Pharma @revealpharma]

Congratulations @GEHealthCare on following in @revealpharma footsteps with a manganese-based MRI agent. This is the way.

Looking forward to images of this new agent vs. standard of care gadolinium-based agents, as well as peer-reviewed chemistry, imaging, & DMPK.

[ITN Editor @itnEditor]

@itnEditor @GEHealthCare Novel manganese-based #macrocyclic Magnetic Resonance Imaging (#MRI) agent could offer an alternative to #gadolinium-based agents: https://t.co/SxpqZ3r1bS

[Reveal Pharma @revealpharma]

Here's a thread with our science...

https://t.co/mleXFaM596

[Reveal Pharma @revealpharma]

This is what a general purpose gadolinium-free MRI contrast agent looks like: Reveal's RVP-001